A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3440-3451

  Kim, Kenneth H ^a   Dmitriev, Igor ^f   O'Malley, Janis P ^b   Wang, Minghui ^f   Saddekni, Souheil ^b   You, Zhiying ^e   Preuss, Meredith A ^c   Harris, Raymond D ^g   Aurigemma, Rosemarie ^h   Siegal, Gene P ^d   Zinn, Kurt R ^b   Curiel, David T ^f   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD5.SSTR TK.RGD; ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CA 125 ANTIGEN; GANCICLOVIR; NEUTRALIZING ANTIBODY; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTIBODY RESPONSE; ARTICLE; ASCITES; BACKACHE; CLINICAL ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; GENE TRANSFER; GYNECOLOGIC CANCER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; INFECTION; INTERNATIONAL NORMALIZED RATIO; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT CANCER; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; SUICIDE GENE THERAPY; SYNDROME; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VIRUS SHEDDING;

ADENOVIRIDAE; AGED; CA-125 ANTIGEN; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; GANCICLOVIR; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; VIRUS REPLICATION;

EID: 84862518298     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2852     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200. (Pubitemid 46606249)
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
5. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006;367:1558-60. (Pubitemid 43674219)
6. Kimball KJ, Numnum TM, Rocconi RP, Alvarez RD. Gene therapy for ovarian cancer. Curr Oncol Rep 2006;8:441-7. (Pubitemid 44697773)
7. Kanerva A, Raki M, Hemminki A. Gene therapy of gynaecological diseases. Expert Opin Biol Ther 2007;7:1347-61. (Pubitemid 47485148)
8. Freeman SM, Abboud CN, Whartenby KA, Pachman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83. (Pubitemid 23333399)
9. Rosenfeld M, Feng M, Michael S, Siegal G, Alvarez R, Curiel D. Adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1995;1:1571-80. (Pubitemid 26030986)
10. Rosenfeld M, Wang M, Siegal G, Alvarez R, Mikheeva G, Krasnykh V, et al. Adenoviral mediated delivery of herpes simplex thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996;74:455-62. (Pubitemid 26261899)
11. Alvarez R, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, et al. Adenoviral mediated suicide gene therapy for ovarian cancer. Mol Ther 2000;2:524-30.
12. Robinson W, Adams J, Marrogi A, Freeman S. Vaccine therapy for ovarian cancer using herpes simplex virus thymidine kinase (HSV-TK) suicide gene transfer technique: a phase I study. Gene Ther Mol Biol 1998;2:31-40.
13. Link C, Eldeman M, Tennant L, Levy J, Moorman D, Seregina T. LTKOSN.1 murine vector producer cell (VPC) for the in vivo delivery of the herpes simplex thymidine kinase (HSV-TK) gene for ovarian cancer. Am Soc Gene Ther 1999; Abstract #915.
14. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1999;72:9706-13. (Pubitemid 28520834)
15. Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 2000;60:6784-7. (Pubitemid 32059138)
16. Vanderkwaak T, Wang M, Navarro J, Rancourt C, Dmitriev I, Krasnykh V, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999;74:227-34. (Pubitemid 29377217)
17. Shah K. Current advances in molecular imaging of gene and cell therapy for cancer. Cancer Biol Ther 2005;4:518-23. (Pubitemid 41351223)
18. Raty JK, Liimatainen T, Unelma Kaikkonen M, Grohn O, Airenne KJ, Yia-Herttuala S. Non-invasive imaging in gene therapy. Mol Ther 2007;15:1579-86. (Pubitemid 47289000)
19. Zinn K, Buchsbaum D, Chaudhuri T, Mountz J, Grizzle W, Rogers B. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high affinity peptide radiolabeled with 99mTc or 188Re. J Nucl Med 2000;41:887-95. (Pubitemid 30266035)
20. Zinn KR, Chaudhuri TR. The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med Mol Imaging 2002;29:388-99. (Pubitemid 34253253)
21. Zinn KR, Chaudhuri TR, Krasnykh VN, Buchsbaum DJ, Belousova N, Grizzle WE, et al. Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 2002;223:417-25. (Pubitemid 34454320)
22. Belousova N, Harris R, Zinn K, Rhodes-Selser MA, Kotov A, Kotova O, et al. Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette. Mol Pharmacol 2006;70:1488-93.
23. Hemminki A, Belousova N, Zinn K, Liu B, Wang M, Chaudri T, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001;4:223-31. (Pubitemid 32851286)
24. Hemminki A, Zinn K, Liu B, Chaudhuri T, Desmond R, Rogers B, et al. In vivo molecular chemotherapy and non-invasive imaging with an infectivity enhanced adenovirus. J Nat Cancer Inst 2002;94:741-49. (Pubitemid 34567958)
25. Matthews K, Noker PE, Tian B, Grimes SD, Fulton R, Schweikart K, et al. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin Cancer Res 2009;15:4131-7.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
27. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21:419-23.
28. Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neurooncol 2003;65:269-78. (Pubitemid 37526819)
29. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007;15:834-40. (Pubitemid 46432005)
30. Xu F, Li S, Lis XL, Guo Y, Zou BY, Xu R, et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009;16:723-30.
31. Rainov NG. APhase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389-401.
32. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single chain antibody (sFv) encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 2000;6:3081-7. (Pubitemid 30637731)
33. Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010;16:5277-87.
34. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;9:553-66. (Pubitemid 34734419)
35. Lee SJ, Kim Y, Jo MY, Kim HS, Jin Y, Kim SU, et al. Combined treatment of tumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking a mild immune response. Oncol Rep 2011;25:63-8.
36. Onion D, Patel P, Pineda RG, James N, Mautner V. Antivector and tumor responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Hum Gene Ther 2009;20:1249-58.
37. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008;8:1581-8.
38. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192-8.
39. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010;70:875-82.
40. Rajecki M, Kangasmaki A, Laasonen L, Escutenaire S, Hakkarainen T, Haukka J, et al. Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad 5/3-Δ24-hNIS. Mol Ther 2011;19:629-31.
41. Yu B, Zhang Y, Zhan Y, Zha X, Wu Y, Zhang X, et al. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep 2011;26:255-64.
42. Xu Y, Hou J, Liu Z, Yu H, Sun W, Xiong J, et al. Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma. J Transl Med 2011;9:39.
43. Leveille S, Samuel S, Goulet ML, Hiscott J. Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 2011;18:435-43.